Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
Romanian Journal of Infectious Diseases ; 24(1):5-13, 2021.
Article in English | Scopus | ID: covidwho-2156252

ABSTRACT

Objective. This study aimed to perform a systematic review of existing literature to assess the outcomes of pregnancy in women with COVID-19 infection and their newborns while estimating the possibility of vertical transmission. Materials and methods. We conducted a systematic literature research using Pubmed and Google Schol-ar covering the period from December 2019 to 20th of November 2020. The review was conducted in ac-cordance with PRISMA guidelines. Outcomes. We included 16 studies – systematic reviews and meta-analyses published between May 2020 and November 2020 – which focused on perinatal outcomes of pregnant women with COVID-19 and 7 case reports of neonates with congenital transmission of COVID-19. Overall, the rate of COVID-19 cases in neonates of COVID-19 positive mothers was 3% with 95% CI [1.86, 4.24]). The preterm birth rate was 16.4% with 95% CI [10.5, 22.3] and the rate of stillbirths and foetal deaths was 1.4% (11 studies, 0 to 4.8%). From the 7 newborns with proved vertical transmission, majority were born preterm, with good birth weight and APGAR score and heterogenous symptoms;4 developed severe symptoms. Overall progress and evolution for both mother and newborn was good. Conclusions. COVID-19 impact on pregnancy outcome is similar to general population in regard to preterm rate and stillbirth rate. Vertical transmission is possible and it seems to occur in about 3% of cases. Overall maternal and perinatal outcome is favourable and clinical presentation of in utero transmission of SARS-CoV-2 in newborns is heterogenous. © 2021, Amaltea Medical Publishing House. All rights reserved.

2.
Romanian Journal of Infectious Diseases ; 23(3):179-182, 2020.
Article in English | Scopus | ID: covidwho-2156247

ABSTRACT

The ongoing coronavirus disease 2019 (COVID-19) outbreak was declared a pandemic by the World Health organization in early March 2020. The disease typically presents with viral respiratory symptoms that could progress to acute respiratory dis-tress syndrome. Emerging evidence suggests different possible dermatologic manifestations of COVID-19, including: acral lesions (pernio-like, pseudo-chillblain), vesicular eruptions, macular and papular exanthema, urticaria, livedoid, purpuric and petechial rashes. However, specific skin manifestations of the COVID-19 disease have not yet been clearly established and the relationship between the appearance of skin lesions and SARS-CoV-2 infection is still unclear. These highly variable skin changes could represent a direct con-sequence of the viral infection, an immunological response to viral nucleotides, adverse reactions to drugs frequently used for the treatment of COVID-19, or other disorders. In a global effort to comprehend the exact cutaneous features of COVID-19, several international dermatological societies have initiated nationwide studies to analyze COVID-19 cutaneous manifestations during this pandemic. This paper represents a literature review of the scientific data available on the clinical characteristics and symptoms of the cutaneous manifestations associated with COVID-19. Such findings are extremely useful in establishing if dermatological manifestations in COVID-19 patients could harbor a diagnostic significance and subsequently be used as prognostic factors for outcomes of COVID-19. © 2020, Amaltea Medical Publishing House. All rights reserved.

3.
Proceedings of the Romanian Academy. Series B, Chemistry, Life Sciences and Geosciences ; 23(1):108-114, 2021.
Article in English | GIM | ID: covidwho-1279171

ABSTRACT

The COVID-19 disease brought numerous hospitalizations and deaths worldwide, which exerted implications not only for health care professionals of different specialties, but also for the general population in need of medical attention - and psoriasis patients make no exception. The COVID-19 pandemic raised multiple issues of concern such as whether immunosuppressant, including biologic therapy may increase the risk of patients with psoriasis to develop the viral infection or to progress more severely;the possibility of a disease flare-up after discontinuation of immunosuppressive therapy;the safety of COVID-19 vaccination in immunocompromised patients including those on immunosuppressive medications. In this review, we aim to bring attention to the coronavirus vaccination among psoriasis population, a fundamental point of interest for dermatologists, rheumatologists and general practitioners, according to the available guidelines and recommendations. Patient education with respect to SARS-CoV-2 vaccination is of great importance and proper counseling by healthcare professionals is essential for a better understanding of the use of vaccines while on immunosuppressive or biologic therapy.

SELECTION OF CITATIONS
SEARCH DETAIL